LivaNova PLC (NASDAQ:LIVN) Shares Sold by Arizona State Retirement System

Arizona State Retirement System reduced its position in LivaNova PLC (NASDAQ:LIVN) by 1.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 15,063 shares of the company’s stock after selling 246 shares during the quarter. Arizona State Retirement System’s holdings in LivaNova were worth $779,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. increased its holdings in shares of LivaNova by 80.8% in the 4th quarter. Pacer Advisors Inc. now owns 8,102 shares of the company’s stock valued at $419,000 after purchasing an additional 3,621 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of LivaNova by 18.9% in the 4th quarter. SG Americas Securities LLC now owns 37,611 shares of the company’s stock valued at $1,946,000 after purchasing an additional 5,990 shares in the last quarter. Diversified Trust Co purchased a new position in shares of LivaNova in the 4th quarter valued at about $626,000. Vanguard Group Inc. increased its holdings in shares of LivaNova by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after purchasing an additional 100,133 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in shares of LivaNova by 93.6% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 18,370 shares of the company’s stock valued at $971,000 after purchasing an additional 8,879 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday. Barclays increased their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price objective on shares of LivaNova in a research note on Wednesday, March 20th. Robert W. Baird increased their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, February 22nd. Finally, Mizuho reissued a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $64.40.

LivaNova Price Performance

LivaNova stock opened at $51.87 on Thursday. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $59.86. The stock has a market capitalization of $2.80 billion, a P/E ratio of 162.10 and a beta of 0.89. The firm’s 50-day moving average is $53.51 and its two-hundred day moving average is $50.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. During the same period last year, the company earned $0.81 EPS. The firm’s revenue for the quarter was up 12.8% compared to the same quarter last year. Equities analysts predict that LivaNova PLC will post 3.01 earnings per share for the current year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.